Cyclo Therapeutics Granted European Patent for Alzheimer's Treatment

 Cyclo Therapeutics, a clinical stage biotechnology company, announced today that it has received notice from the European Patent Office of a decision to grant European patent application No. 19805439.7, titled "Methods for Treating Alzheimer's Disease," under European patent number 3873604B. Cyclo Therapeutics is committed to using science and innovation to develop life-changing medicines for patients and families living with diseases. According to the notification, the judgement will be made public and go into effect on August 21, 2024, when it appears in European Patent Bulletin 24/34.

"This notice of decision to grant the European patent application represents an important milestone for our Alzheimer's disease asset as well as a valuable component of our patent estate," stated Cyclo Therapeutics CEO N. Scott Fine. We continue to have hope that Trappsol® CycloTM from Cyclo Therapeutics may play a big part in the treatment arsenal given the urgent need for innovation and therapeutic treatments to address early onset Alzheimer's disease.